This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

SA4503 8-Week Study in Major Depressive Disorder (MDD)

This study has been completed.
Information provided by:
M's Science Corporation Identifier:
First received: October 29, 2007
Last updated: December 17, 2008
Last verified: December 2008
The purpose of this study is to determine the efficacy of SA4503 compared to placebo in the treatment of subjects with major depressive disorder (MDD). Secondary, to evaluate the safety of SA4503 compared to placebo in subjects with MDD.

Condition Intervention Phase
Depressive Disorder, Major Drug: placebo Drug: SA4503 Low Drug: SA4503 High Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment With SA4503, Once Daily for 8 Weeks, in Subjects With Major Depressive Disorder

Further study details as provided by M's Science Corporation:

Primary Outcome Measures:
  • Montgomery-Åsberg Depression Rating Scale (MADRS) [ Time Frame: 8 weeks ]

Estimated Enrollment: 150
Study Start Date: November 2007
Study Completion Date: September 2008
Arms Assigned Interventions
Placebo Comparator: P
Drug: placebo
placebo, oral administration, once daily for 8 weeks
Experimental: A1
Drug: SA4503 Low
Low dose, oral administration, once daily for 8 weeks
Experimental: A2
Drug: SA4503 High
High dose, oral administration, once daily for 8 weeks

Detailed Description:
Further study details as provided by M's Science Corporation:

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female between the ages of 18 and 65 (inclusive)
  • Diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria and a shortened MINI evaluation
  • HAM-D17 score of >/= 21 and a severity score of at least 2 for Item 1 (depressed mood) at both Screening and Baseline
  • Current depressive episode of at least 3 months duration, and significant depressed mood and anhedonia in the 4 weeks prior to Screening.

Exclusion Criteria:

  • Subjects who have received fluoxetine within 1 month prior to Baseline or any other antidepressant within 2 weeks prior to Baseline, or any unlicensed medication within 1 month before Screening
  • Subjects who require psychotropic medication other than the study medication
  • Subjects who started psychotherapy within 4 months prior to Screening
  • Subjects who currently (i.e., in the month prior to Screening) meet DSM-IV criteria for bipolar syndrome or psychotic depression or severe somatoform or eating disorders
  • Subjects who have a primary diagnosis of anxiety
  • Subjects who regularly use sleeping medication more than 3 times per week
  • Subjects who have major psychiatric or neurologic disorders other than MDD
  • Subjects with depression secondary to stroke, cancer, or other severe medical illness
  • Subjects who have a history of alcohol or substance dependence(within 1 year prior to Screening)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00551109

Helsinki, Finland
Jyväskylä, Finland
Kuopio, Finland
Tampere, Finland
Turku, Finland
Sponsors and Collaborators
M's Science Corporation
Principal Investigator: Björn Appelberg, MD, PhD Helsinki University Central Hospital, Department of Psychiatry
  More Information

Responsible Party: Kazunori Yoshikawa, M's Science Corporation Identifier: NCT00551109     History of Changes
Other Study ID Numbers: ME1-1
EudraCT number: 2007-002740-16
Study First Received: October 29, 2007
Last Updated: December 17, 2008

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
SA 4503
Nootropic Agents processed this record on September 21, 2017